key: cord-0701372-exxbe3qs authors: Finsterer, Josef; Scorza, Fulvio Alexandre; Scorza, Carla Alessandra; Fiorini, Ana Claudia title: Ischemic stroke in 455 COVID-19 patients date: 2022-02-14 journal: Clinics (Sao Paulo) DOI: 10.1016/j.clinsp.2022.100012 sha: 23f159b2f871a05c258a467e6c982fa3e293b947 doc_id: 701372 cord_uid: exxbe3qs There is increasing evidence that COVID-19 can be associated with ischemic stroke (COVID-stroke). The frequency and pathogenesis of COVID-stroke, however, remains largely unknown. This narrative review aimed at summarizing and discussing current knowledge about frequency and pathogenesis of COVID-stroke in 455 patients collected from the literature. COVID-stroke occurs in all age groups and predominantly in males. The anterior circulation is more frequently affected than the posterior circulation. COVID-stroke is most frequently embolic. The severity of COVID-stroke ranges from NIHSS 3 to 32. Cardiovascular risk factors are highly prevalent in patients with COVID-stroke. COVID-stroke occurs simultaneously with the onset of pulmonary manifestations or up to 40 days later. Clinical manifestations of COVID-19 are most frequently mild or even absent. The majority of patients with COVID-stroke achieve complete or partial recovery, but in one-quarter of patients, the outcome is fatal. In conclusion, the frequency of ischemic stroke has not increased since the outbreak of the SARS-CoV-2 pandemic. COVID-stroke predominantly affects males and the anterior circulation. COVID-stroke is multifactorial but predominantly embolic and more frequently attributable to cardiovascular risk factors than to coagulopathy. This study shows that COVID-stroke occurs in all age groups and predominantly in males. The anterior circulation is more frequently affected than the posterior circulation. According to the TOAST classification, COVID-stroke is most frequently embolic. Particularly COVID-19 patients with classical cardiovascular risk factors develop SARS-CoV-2 associated stroke. Coagulopathy is less common among patients with COVID-stroke. The severity of COVID-stroke has a broad range from NIHSS 3 to 32. COVID-stroke may occur simultaneously with the onset of pulmonary manifestations or up to 40 days later. Clinical manifestations of COVID-19 are most frequently mild or even absent, which is in contrast to previous studies. The vast majority of patients survive COVID-strokes with complete or partial remission, but in one-quarter of patients, the outcome is fatal. Concerning the frequency of ischemic stroke in COVID-19 patients, variable results have been provided (Table 2) . Altogether, the frequency of COVID-stroke ranged from 0.5-5.9% (Table 2 ). In a systematic review of 212 studies on the neurological manifestations of COVID-19, COVID-stroke was reported in 0.5-5.9% of patients. [3] In a meta-analysis of 108571 COVID-19 patients, ischemic stroke was diagnosed in 1328 patients (1.22%). [4] In this study, patients with COVID-stroke were older and more likely to have hypertension, diabetes, coronary heart disease, or severe infection than COVID-19 patients without stroke. [4] Compared to stroke patients without COVID-19, patients with COVID-stroke were younger, had a higher NIHSS, higher frequency of large vessel disease, and higher in-hospital mortality. [4] When studying 2050 COVID-19 patients, 1.02% experienced a COVID-stroke. [5] In a study of 214 COVID-19 patients, 4.9% experienced a COVID-stroke. [6] In a study from 2 hospitals in New York, 16 COVID-strokes were identified. [7] In a study of 3165 patients undergoing thrombectomy, 104 were positive for SARS-CoV-2. [8] COVID-stroke was associated with young age, male sex, diabetes, black race, Hispanic ethnicity, intubation, acute coronary syndrome, acute renal failure, and prolonged duration of hospitalization. [8] The odds for in-hospital death were increased > 4 fold. [8] The incidence of COVID-stroke was reported as 1%-6% as of October 2020, but mortality of COVID-stroke can be up to 38% (Table 2 ). [9] A recent meta-analysis has shown that the frequency of COVID-stroke is not increased but that the outcome of these patients is worse as compared to patients without ischemic stroke. [10] A meta-analysis of 28 studies confirmed that the frequency of COVID-stroke is low, but those with COVID-stroke have a poorer prognosis and higher mortality than those with COVID-19 alone. [11] Comparing previous studies with the present study, demographic parameters were comparable as well as a number of risk factors, the severity of the stroke, and latency between onset of COVID-19 and occurrence of the stroke (Table 2) . However, the present study was at variance to previous studies regarding the fact that stroke occurred irrespective of the severity of COVID-19. According to previous studies, COVID-stroke was more prevalent among patients with severe COVID-19 compared to those with mild COVID-19. COVID-stroke was also more prevalent among those with a high number of risk factors as compared to those with none or few risk factors. Outcomes, particularly mortality, varied considerably between the COVID-stroke studies (6.7%-71%) ( Table 2 ). This may be due to variable stroke severity, variable COVID-19 severity, and variable intensity and quality of the treatment applied. The pathophysiology of COVID-stroke is not completely understood, but proposed mechanisms include endothelial inflammation, stasis, increased procoagulant factors in the blood (hypercoagulability), and cardiac compromise, consistent with Virchow's triad (mirco/microangiopathy, impaired hemodynamic, altered blood composition [hypercoagulability]). [12] Coagulopathy and vascular endothelial dysfunction have been proposed as complications of COVID-19. [13] There is evidence of direct invasion of endothelial cells by SARS- The contribution of complement-mediated endothelial injury has also been suggested. [14] Hyperviscosity has been demonstrated in a series of fifteen critically ill patients on the ICU. [15] In a study of 24 patients with severe COVID-19 pneumonia requiring artificial ventilation, standard coagulation testing, and other assays revealed normal or slightly prolonged Prothrombin Time (PT) and activated Partial Thromboplastin Time (aPTT), normal or increased platelet counts, increased fibrinogen, and increased D-dimer. [16] "Hypercoagulability" was poorly defined in most of the studies included in this review. It is unclear if hypercoagulability was defined by elevated fibrinogen, prolonged prothrombin time, prolonged PTT, or by elevated D-dimer. [17] In a study of 3 patients with COVID-stroke, D-dimer was elevated in three. [18] Unfortunately, no reference limits were provided for other coagulation parameters. [18] Reference limits for coagulation parameters were also missing in other studies. [19, 20] However, elevated D-dimer in a patient with a viral infection or even bacterial superinfection is not unusual and does not necessarily suggest hypercoagulability. An argument in favor of hypercoagulability in COVID-19 patients, however, is the fact COVID-19 is associated with an increased risk of thrombosis. [21, 22] Thrombotic events more frequently occur on the venous side (96%) than on the arterial side (4%). [22] There are not only indications for an increased prevalence of superficial and deep venous thrombosis [23] but also for pulmonary embolism, [24] mesenteric thrombosis, [25] sinus venous thrombosis, [26] and atrial thrombosis. [27] Whether deep venous thrombosis and Patent Foramen Ovale (PFO) contribute to the risk of COVID-stroke has not been systematically investigated but is conceivable. The risk of ischemic stroke increases with the severity of COVID-19. Limitations of the study were that the publication period of interest was short, as in other studies (Table 2) , that several studies, particularly those investigating larger cohorts, did not provide detailed information about individual patients with COVID-stroke, and that only a few studies investigated the pathophysiology of ischemic stroke systematically. [18] Conclusions According to currently available data, the overall prevalence and incidence of ischemic stroke did not increase since the outbreak of the SARS-CoV-2 pandemic, [28] [29] [30] but prospective studies are warranted to solve this question. COVID-stroke predominantly affects males, the anterior circulation and is multifactorial. Since most patients with COVID-stroke also carry classical cardiovascular risk factors, a causal relation between stroke and COVID-19 is rather unlikely. Whether endothelial injury or hypercoagulability contribute to the pathophysiology of ischemic stroke in COVID-19 patients remains speculative. Hypercoagulability does not seem to play a major role in the pathophysiology of COVID-stroke. Following these conclusions, the stroke of undetermined etiology remains a common subtype of COVID-stroke. Finsterer J: Design, literature search, discussion, first draft, critical comments. Scorza FA, Scorza CA, Fiorini AC: Literature search, discussion, critical comments, final approval. The authors declare no conflicts of interest. Involvement of the nervous system in COVID-19: The bell should toll in the brain A Prospective Study of Neurologic Disorders in Hospitalized Patients With COVID-19 in Neurological manifestations of COVID-19: a systematic review and meta-analysis of proportions Stroke in COVID-19: A systematic review and metaanalysis Stroke: Incidence and Etiological Description in a High-Volume Center Neurologic Manifestations of Hospitalized Patients With Coronavirus Disease Etiologic subtypes of ischemic stroke in SARS-CoV-2 patients in a Cohort of Endovascular thrombectomy in acute ischemic stroke patients with COVID-19: prevalence, demographics, and outcomes Acute ischemic and hemorrhagic stroke in COVID-19: mounting evidence Ischemic stroke occurs less frequently in patients with COVID-19: a multicenter cross-sectional study Stroke and novel coronavirus infection in humans: a systematic review and meta-analysis Acute stroke in a young patient with coronavirus disease 2019 in the presence of patent foramen ovale Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study Complement associated microvascular injury and thrombosis in the pathogenesis of severe COVID-19 infection: a report of five cases COVID-19-associated hyperviscosity: a link between inflammation and thrombophilia? Hypercoagulability of COVID-19 patients in intensive care unit: A report of thromboelastography findings and other parameters of hemostasis Large-vessel stroke as a presenting feature of Covid-19 in the young Arterial and venous strokes in the setting of COVID-19 intravenous tPA for acute ischemic stroke in patients with COVID-19 Ischaemic strokes associated with COVID-19: is there a specific pattern? COVID-19 and venous thromboembolism Incidence of thrombotic complications in critically ill ICU patients with COVID-19 Mondor's disease in SARS-CoV-2 infection: a case of superficial vein thrombosis in the era of COVID-19 Acute high-risk pulmonary embolism requiring thrombolytic therapy in a COVID-19 pneumonia patient despite intermediate dosing deep vein thromboprophylaxis Acute mesenteric thrombosis in two patients with COVID-19. Two cases report and literature review A case of Coronavirus Disease 2019 presenting with seizures secondary to cerebral venous sinus thrombosis Right atrial thrombus in a patient with COVID-19 pneumonia: a case report Request of hospital care dropped for TIA but remained stable for stroke during COVID-19 pandemic at a large Italian university hospital The stroke mothership model survived during COVID-19 era: an observational single-center Impact of COVID-19 on stroke admissions, treatments, and outcomes at a comprehensive stroke centre in the United Kingdom COVID-19-related strokes are associated with increased mortality and morbidity: A multicenter comparative study from Bengaluru, South India Neurologic manifestations in 1760 COVID-19 patients admitted to Papa Giovanni XXIII Hospital SARS-CoV-2 and stroke in a new york healthcare system Stroke in COVID-19: a single-centre initial experience in a hotspot of the pandemic COVID-19 and ischemic stroke: clinical and neuroimaging findings Humanitas COVID-19 Task Force. Venous and arterial thromboembolic complications in COVID-19 patients admitted to an academic hospital in COVID-19-related intracranial imaging findings: a large single-centre experience High risk of thrombosis in patients with severe SARS-CoV-2 infection: a multicenter prospective cohort study Ischaemic stroke associated with COVID-19 in dialysis patients Acute Ischemic Hemorrhagic Stroke in Two Unfractionated Heparin in SARS-CoV-2 Pneumonia: Ischemic Stroke Case Report Vasculitis-related stroke in young as a presenting feature of novel coronavirus disease (COVID19) -Case report Ischemic-hemorrhagic stroke in patients with Covid-19 COVID-19 presenting with agraphia and conduction aphasia in a patient with left-hemisphere ischemic stroke Supra and infratentorial massive strokes in previously healthy young patients with SARS-CoV-2. The role of neurosurgery Cerebral Herniation Secondary to Stroke-Associated Hemorrhagic Transformation, Fulminant Cerebral Edema in Setting of COVID-19 Associated ARDS and Active Malignancy Cerebellar infarction requiring surgical decompression in patient with COVID 19 pathological analysis and brief review Possible affective cognitive cerebellar syndrome in a young patient with COVID-19 CNS vasculopathy and stroke Large and Small Cerebral Vessel Involvement in Severe COVID-19: Detailed Clinical Workup of a Case Series Coronavirus Disease 2019-Related Acute Ischemic Stroke: A Case Report Multiple embolic stroke on magnetic resonance imaging of the brain in a COVID-19 case with persistent encephalopathy Acute Ischemic and Hemorrhagic Stroke and COVID-19: Case Series Mechanical Thrombectomy of COVID-19 positive acute ischemic stroke patient: a case report and call for preparedness Acute Ischemic Stroke and COVID-19: An Analysis of 27 676 Patients Risk Factors, and Clinical and Etiological Characteristics of Ischemic Strokes in COVID-19-Infected Patients: A Systematic Review of Literature SVIN Multinational Registry and Task Force. Stroke etiologies in patients with COVID-19: the SVIN COVID-19 multinational registry Ischemic stroke associated with COVID-19: a systematic review and meta-analysis Hemorrhagic and ischemic stroke in patients with coronavirus disease 2019: incidence, risk factors, and pathogenesisa systematic review and meta-analysis Frequency of Neurologic Manifestations in COVID-19: A Systematic Review and Meta-analysis A case-based systematic review on the SARS-COVID-2-associated cerebrovascular diseases and the possible virus routes of entry CAPACITY-COVID Collaborative Consortium. Risk, Clinical Course, and Outcome of Ischemic Stroke in Patients Hospitalized With COVID-19: A Multicenter Cohort Study Associated Stroke-A Single Centre Experience Artificial Ventilation Embolic Stroke of Unknown Significance Left/right Internal Carotid Artery; LVO, Large Vessel Occlusion; LVPS; Latency Between Positive Virus-PCR and onset of stroke Left/right Median Cerebral Artery; mf, Multifocal; MIA, Microangiopathy; mRS Number of Patients; nr Left/right Posterior Cerebral Artery; PFO, Patent Foramen Ovale; PICAS/D, Left/right Posterior Inferior Cerebelli Artery Ranking Scale; SC, Stroke Classification According to TOAST criteria Severity of COVID-19 infection at time of stroke onset ACAS/D, Left/right Anterior Cerebral Artery; ACLA, Anti-Cardiolipin-Antibodies; AF, Atrial Fibrillation/Atrial Flutter; AHT, Arterial Hypertension, as, Asymptomatic; AP, Angiopathy (macro-